Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 29.18M P/E - EPS this Y - Ern Qtrly Grth -
Income -13.77M Forward P/E 1.94 EPS next Y - 50D Avg Chg 46.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 31.00%
Dividend N/A Price/Book 20.67 EPS next 5Y - 52W High Chg -49.00%
Recommedations 3.00 Quick Ratio 0.54 Shares Outstanding 149.93M 52W Low Chg 121.00%
Insider Own 14.92% ROA -226.49% Shares Float 120.20M Beta 3.36
Inst Own 6.33% ROE - Shares Shorted/Prior -/- Price 0.31
Gross Margin - Profit Margin - Avg. Volume 26,631 Target Price -
Oper. Margin - Earnings Date - Volume 61,370 Change 0.00%
About ALPHA COGNITION INC

Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

ALPHA COGNITION INC News
04/03/24 Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
06:00 AM Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
03/20/24 Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EDT.
03/08/24 Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
03/05/24 Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024
03/01/24 Alpha Cognition to Present at the Life Science Investor Forum March 7th
02/22/24 Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
02/12/24 Alpha Cognition Provides Business Update
01/19/24 Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
12/22/23 Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
12/07/23 Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
12/04/23 Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
11/28/23 Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update
11/08/23 Alpha Cognition Announces Third Closing of Private Placement and Continuation of the Offering
10/16/23 Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
09/27/23 Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
08/31/23 Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
08/22/23 Alpha Cognition Announces Second Quarter and Six Months Ended 2023 Results and Provides Corporate Update
08/14/23 Alpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer’s Disease
06/23/23 Life Science Investor Forum: Presentations Now Available for Online Viewing
ACOGF Chatroom

User Image Bioinvester001 Posted - 20 hours ago

$ACOGF Yesterday the company filed a S1. In April of 2020, Zillow filed a S1, and in July they were uplisted to NASDAQ. That is the purpose of the filing with this company. I think with the FDA approval in July, the uplistng to NASDAQ could then be completed and the sp will likely be very much to the upside. Buckle up!

User Image Bioinvester001 Posted - 04/30/24

$ACOGF Public filing today was for the closing of shares sold to several entities some time ago. Nothing new here, and looks like the company is preparing for the NASDAQ uplisting, and appears to be working in keeping the house in good order. Could see a corporate update soon.

User Image valeryam Posted - 04/30/24

$ACOGF There was a new SEC filing today. Is it a Public offering? I think it’s a closing of the offering actually. Has anyone reviewed it?

User Image Bioinvester001 Posted - 04/26/24

$ACOGF Having the NDA accepted is a huge deal, as the FDA looks at many factors that have to be in place before even accepting the NDA application. The company is now way ahead of the other companies that are now developing drugs which also do not have the safety profile that the company's drug has. Do your DD and watch the company's last presentation. This company is way off the radar, and I see big upside.

User Image Squeezepepper Posted - 04/24/24

$ACOGF either way; however, with approval, the SP should pivot up. Not sure to what extent and if it'll rise enough to hold above $1 for any length. I haven't entered because July is a ways away and seems to be eroding very slowly or somewhat bar coding until then.

User Image Perry_Allback Posted - 04/24/24

$ACOGF In other words, Alpha Cognition's drug, which is very likely to receive FDA approval in July 2024, is not a big deal and not worth talking about because there is already a similar drug on the market? So no "holy grail" in Alzheimer's treatment and it's all just hot air so far?

User Image Logic102 Posted - 04/22/24

$ACOGF Minimal activity because it's difficult to get excited about reformulated Pablum that is easier to digest but it's still Pablum. It is a better choice than Leqembi and Aduhelm but that's not saying much.

User Image Squeezepepper Posted - 04/19/24

$ACOGF why the minimal activity on this board?

User Image Bioinvester001 Posted - 04/12/24

$ACOGF Adding!

User Image Bioinvester001 Posted - 04/11/24

$ACOGF NASDAQ listing in the works. This will put this company on the radar. One day closer to FDA approval in July for their ALZ drug. Updates soon.

User Image Bioinvester001 Posted - 04/05/24

$ACOGF July not that far away for FDA approval which will be a watershed in treatment for ALZ. Price could be $400 with 0 to 10 dollars copay, and the market is tremendous for this drug. Long term treatment care is the focus as well.

User Image FlowerInTheCellar Posted - 04/04/24

$ACOGF https://www.businesswire.com/news/home/20240403813914/en/

User Image FlowerInTheCellar Posted - 04/03/24

$ACOGF https://goto.webcasts.com/viewer/event.jsp?ei=1664514&tp_key=8652454af5 conference presentation it will be start at 6pm European time (berlin)

User Image TimingTimingTiming Posted - 1 month ago

$ACOGF Long

User Image FlowerInTheCellar Posted - 03/23/24

$ACOGF https://www.businesswire.com/news/home/20240320178535/en/

User Image Aruba1 Posted - 03/21/24

$ACOGF https://www.alz.org/alzheimers-dementia/treatments/lecanemab-leqembi

User Image Bioinvester001 Posted - 03/14/24

$ACOGF This is likely the only drug to be approved for the treatment of ALZ during the past decade. Tremendous TAM as it is geared for beginning to mild cases, and long term care is the key. Nil side effects seen, and listing by NASDAQ up for approval.

User Image FlowerInTheCellar Posted - 03/14/24

$ACOGF https://www.nasdaq.com/press-release/life-science-virtual-investor-forum-presentations-now-available-for-online-viewing 7. march´24 Hello folks. If you are interested in the presentation, register for free and take a look. I looked at it and am happy with the findings

User Image Bioinvester001 Posted - 03/13/24

$ACOGF One day closer for July approval. Eli Lilly delayed for their drug and Acadia has stopped their trials for their drug as well. No one up for approval but ACOGF for ALZ in the past ten years. Also, NASDAQ listing up for approval.

User Image Aruba1 Posted - 03/10/24

$ACOGF at approval they will sell shares . as discussed this past week. they have enough cash till then. My opinion, with approval, they will get bought out . so no need to sell!!

User Image jumptime Posted - 03/08/24

$ACOGF Good for us: Eli Lilly says FDA delays approval of Alzheimer’s drug in surprise move

User Image deepf00kinvalue Posted - 03/07/24

$ACOGF This one is very much under the radar.

User Image Bioinvester001 Posted - 03/05/24

$ACOGF One day closer to July approval. First ALZ drug up for approval in ten years. Look for SP to move up on news for this company that is completely off the radar.

User Image Ninja_Tradez Posted - 2 months ago

📢 $ACOGF - Alpha Cognition to Present at the Life Science Investor Forum March 7th https://newsfilter.io/a/5ba8fc25b1d7d814f40d57e2f13ff9a6

User Image Perry_Allback Posted - 02/28/24

$ACOGF When will the price rocket finally take off here? 🚀

User Image jumptime Posted - 02/27/24

$ACOGF One of these days....

User Image FlowerInTheCellar Posted - 02/22/24

$ACOGF https://www.businesswire.com/news/home/20240222276486/en/

User Image jumptime Posted - 02/22/24

$ACOGF Why this isn't on a tear - I have no idea.

User Image g0eCK Posted - 02/16/24

$ACOGF interesting. Someone having a good source for DD? The corporate presentation seems a bit uninformative towards the pivotal trial... Maybe good timing to open a position here

User Image jumptime Posted - 02/15/24

$ACOGF Nice volume last couple of days.